Bio-Path gets patent for nucleic acid drug platform

By The Science Advisory Board staff writers

February 10, 2021 -- The U.S. Patent and Trademark Office has granted a patent to Bio-Path Holdings for its nucleic acid drug platform, expanding protections for the company's DNAbilize technology.

Bio-Path was awarded U.S. patent No. 10,898,506 titled, "P-ethoxy nucleic acids for liposomal formulation."

On February 23, the company expects to be issued U.S. patent No. 10,927,379 for its lead product candidate prexigebersen, a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).

Researchers use modified CRISPR tool to manipulate the epigenome
Bioengineers have developed a new way to engineer the human epigenome (chemical changes in the DNA) using a modified CRISPR-Cas9 system to target and...
Improving the safety of gene therapies 2 different ways
Two groups of researchers have developed unique approaches to overcome the limitations of delivery of gene editing therapeutics. In a pair of new papers,...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter